🟢 Corcept Therapeutics is trading 4.64% up in pre-market after positive Phase 2 BELLA results

Corcept Therapeutics is trading at $91.17, up 4.64% in pre-market on October 27 after positive Phase 2 BELLA results announced October 26.

• Among 95 patients, the Lifyorli combination showed 7.2-month median progression-free survival and a 59% objective response rate.
• Shares closed at $87.12 on October 26, following a 20.13% fall on October 23, per the supplied price context.
• BELLA was the clearest identified company-specific catalyst; pre-market volume data was not provided.